KalVista Pharmaceuticals, Inc. (KALV)

12.08 +0.02 (+0.17%) 市場開市。 截至 10:39AM EDT。

KalVista Pharmaceuticals, Inc.

55 Cambridge Parkway
Suite 901 East
Cambridge, MA 02142
United States
857 999 0075
https://www.kalvista.com

版塊: Healthcare
行業: Biotechnology
全職員工: 118

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Benjamin L. Palleiko	CEO & Director	707.1k	無	1966
Dr. Christopher M. Yea Ph.D.	Chief Development Officer	640.23k	無	1964
Dr. Edward P. Feener Ph.D.	Chief Scientific Officer	506k	無	1960
Mr. Ryan Baker	Head of Investor Relations	無	無	無
Mr. Brian Krex J.D.	General Counsel	無	無	1968
Jarrod Aldom	Vice President of Corporate Communications	無	無	無
Ms. Rachel M. Morten	Senior Vice President of Regulatory Affairs & QA	無	無	無
Dr. Michael D. Smith Pharm.D.	Senior Vice President of Development	無	無	1980
Dr. Paul K. Audhya M.B.A., M.D.	Chief Medical Officer	無	無	1973
Ms. Nicole Sweeny	Chief Commercial Officer	無	無	1976

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

公司管治

截至 2024年5月1日 止，KalVista Pharmaceuticals, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：7；董事會：7；股東權利：5；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。